cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Hardyanto Soebono
Contact Email
hardyanto@ugm.ac.id
Phone
+62274-560300
Journal Mail Official
jmedscie@ugm.ac.id
Editorial Address
Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Farmako Street, Sekip Utara ,Yogyakarta 55281 Indonesia
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Biomedicine and Clinical Sciences
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 30323134     DOI : https://doi.org/10.22146/inajbcs.v56i01.11961
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience
Indonesian Journal of Biomedicine and Clinical Sciences (InaJBCS) aims to promote the translational of basic research into clinical studies and of clinical evidence into practice. InaJBCS publishes studies that substantially enhance our standing of disease etiology and physiology; the development of prognostic and diagnostic technologies; trials that test the efficacy of specific interventions and those that compare different treatments. InaJBCS invites authors to submit articles in the fields of biomedical sciences including biomedical genetics, bioinformatics, cardiovascular medicine, endocrinology, gastroenterology, geriatrics, infectious diseases, medical oncology, physiology, pharmacology and toxicology, and phytomedicine medicine.
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 15 Documents
 1   2 
Search results for , issue "Vol 57 No 4 (2025)" : 15 Documents clear
Modulation of inflammatory pathways in ischemic stroke rats by hypoxia-primed umbilical cord mesenchymal stem cells (UC-MSCs): Implications for IFN-γ and IL-10 signaling Fahreza, Rakha; Setiawan, Eko; Trisnadi, Setyo; Putra, Agung; Hidayah, Nurul; Fikriya Novita Sari; Ibrahim, Sugeng
Indonesian Journal of Biomedicine and Clinical Sciences Vol 57 No 4 (2025)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v57i4.24529

Abstract

Ischemic stroke is a major global cause of disability and mortality. Inflammation plays a central role in its pathogenesis, characterized by elevated pro-inflammatory cytokines such as IFN-γ and reduced anti-inflammatory cytokines like IL-10. Mesenchymal stem cells (MSCs), especially those derived from the umbilical cord (UC-MSCs), exhibit enhanced immunomodulatory potential when preconditioned under hypoxia. This study aims to evaluate the effect of hypoxic-preconditioned UC-MSCs administration on IFN-γ and IL-10 levels in an ischemic stroke rat model. This in vivo experimental study employed a randomized posttest-only control group design with four groups of male Wistar rats (n=6 each), ranging from healthy controls, untreated group to stroke-induced groups treated with hypoxic UC-MSCs at different doses (1.5x106 and 3x106). IFN-γ and IL-10 levels in brain tissue of each group were measured via ELISA. Significant reduction in IFN-γ and elevation in IL-10 were observed in UC-MSC-treated groups, particularly at the 3×10⁶ cell dose compared to the untreated ischemic group (p<0.05). Hypoxic UC-MSCs reduce post-stroke inflammation by lowering IFN-γ and enhancing IL-10, indicating a promising immunomodulatory potential.
The relationship between the quality of life diabetic patients with family function and social support at the Endocrine Polyclinic of the Dr. Zainoel Abidin Regional General Hospital (RSUDZA), Banda Aceh Maha, Inike Gujamela; Yani, M.; Juwita; Salawati, Liza; Syahrizal; Muhammad Antor Riady; Agus Hendra Al Rahmad
Indonesian Journal of Biomedicine and Clinical Sciences Vol 57 No 4 (2025)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v57i4.18108

Abstract

Diabetes mellitus (DM) is a chronic, non-communicable disease that affects patients quality of life (QoL), which can be influenced by family function and social support. This study aimed to evaluate the relationship betweenfamily function social support, and QoL of patients with DM at the Endocrine Polyclinic of RSUDZA Banda Aceh. This was an analytical observational study with a cross-sectional design, employing convenience sampling methods of 96 respondents and using self-report instruments. Data were analyzed using the Spearman test at a 95% confidence interval and α=0.05. The results showed that 86.2% of respondents had good family function, 72.9% had good social support, and 82.3% had a good QoL. There was a significant relationship between familyfunction, social support, and quality of life (p<0.05). In conclusion improving family functioning and social support may enhance the QoL of patients with DM.
Safety and efficacy of ontamalimab in inflammatory bowel disease: A systematic review and dose- response meta-analysis Setyobudi, Assyadilla Kirana; Yudianto, Valentino Ryu; Hariftyani, Arisvia Sukma; Gatot Soegiarto
Indonesian Journal of Biomedicine and Clinical Sciences Vol 57 No 4 (2025)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v57i4.20500

Abstract

Inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, involve chronic inflammation of the digestive tract. The incidence of IBD has been increasing globally, posing a growing burden despite advancements in treatment. Novel therapies targeting adhesion molecules such as MAdCAM-1 show promise by specifically inhibiting lymphocyte infiltration into the gut, potentially offering safer and more effective treatment options. This meta-analysis and systematic review were conducted to provide efficacy and safety analysis of ontamalimab for IBD treatment. Dose-response (DRMA), network (NMA), and random effect meta-analysis were conducted to extract clinical response, clinical remission, biomarker change, and adverse events of ontamalimab. Studies were retrieved from PubMed, Cochrane, and EMBASE to describe the pooled risk ratio (RR) and heterogeneity was determined if I2 >50%. RoB2 tool and ROBINS-I were used to assess risk of bias in RCT and clinical trial studies, respectively. The result was considered significant if p<0.05. A total of 670 studies were screened, resulting in 8 multicentre studies. There were significant differences in clinical response (RR: 1.39; 95%CI: 1.12–1.73; p = 0.003; I2= 35%), clinical remission (RR: 1.72; 95%CI: 1.17–2.53; p=0.006; I2= 26%), mean change of FC (RR: 624.29; 95%CI: 543.28-705.29; p<0.001; I2= 0%), mean change of CRP serum (RR: 9.71; 95%CI: 7.12–12.3; p<0.001), and mean MAdCAM-1 serum level (RR: 235.57; 95%CI: 203.80–267.33; p <0.001) between ontamalimab 75 mg and placebo after 12 wk of treatment. Meanwhile, adverse events from both groups were similar to those observed in patients treated with either placebo or ontamalimab. This study concluded that ontamalimab 75mg demonstrated significant efficacy in treating IBD, achieving superior outcomes in clinical response and clinical remission compared to placebo. Importantly, no cases of PML and significant adverse events were detected, indicating a favorable safety profile relative to other anti-MAdCAM-1 therapies.
Secondary syphilis psoriasiform in HIV-infected patients: A case series Fitriani, Katia; Alessandro Alfieri; Nurwestu Rusetiyanti; Devi Artami Susetiati; Niken Trisnowati; Satiti Retno Pudjiati
Indonesian Journal of Biomedicine and Clinical Sciences Vol 57 No 4 (2025)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v57i4.26999

Abstract

Psoriasiform secondary syphilis is an uncommon and diagnostically challenging variant of secondary syphilis that can closely mimic psoriasis vulgaris, particularly in people with HIV. This case series adds to the limited literature from resource-limited settings by illustrating how psoriasiform secondary syphilis may be misinterpreted as psoriasis both clinically and histopathologically, and how repeated clinicopathologic correlation is essential to avoid inappropriate immunosuppression. We reported three HIV-infected male patients who presented with generalized psoriasiform erythematous scaly plaques, some with palmoplantar involvement, initially diagnosed as psoriasis. One patient had been treated with methotrexate for severalmonths without clinical improvement. Serologic testing in all cases demonstrated active syphilis with reactive nontreponemal and treponemal tests, including a very high venereal disease research laboratory (VDRL) titer in one patient, and all were confirmed HIV-positive. Initial histopathologic examinations variably suggestedsecondary syphilis or psoriasis; in two patients, repeat biopsy or deeper sectioning was required to reveal plasma cell–rich perivascular infiltrates and vascular changes consistent with secondary syphilis, while one case was ultimately considered to represent coexistence of psoriasis and syphilis. All patients received intramuscularbenzathine penicillin G according to syphilis stage, with additional topical or systemic antiinflammatory therapy when indicated, and showed clinical improvement. In conclusion, psoriasiform secondary syphilis should be routinely considered in the differential diagnosis of psoriasiform eruptions in individuals with sexuallytransmitted infection risk or known HIV infection, and that discrepant clinical, serologic, and histopathologic findings warrant repeat biopsy, deeper sectioning, and multidisciplinary review.
Safety and efficacy of ontamalimab in inflammatory bowel disease: A systematic review and dose- response meta-analysis Setyobudi, Assyadilla Kirana; Yudianto, Valentino Ryu; Hariftyani, Arisvia Sukma; Gatot Soegiarto
Indonesian Journal of Biomedicine and Clinical Sciences Vol 57 No 4 (2025)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v57i4.20500

Abstract

Inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, involve chronic inflammation of the digestive tract. The incidence of IBD has been increasing globally, posing a growing burden despite advancements in treatment. Novel therapies targeting adhesion molecules such as MAdCAM-1 show promise by specifically inhibiting lymphocyte infiltration into the gut, potentially offering safer and more effective treatment options. This meta-analysis and systematic review were conducted to provide efficacy and safety analysis of ontamalimab for IBD treatment. Dose-response (DRMA), network (NMA), and random effect meta-analysis were conducted to extract clinical response, clinical remission, biomarker change, and adverse events of ontamalimab. Studies were retrieved from PubMed, Cochrane, and EMBASE to describe the pooled risk ratio (RR) and heterogeneity was determined if I2 >50%. RoB2 tool and ROBINS-I were used to assess risk of bias in RCT and clinical trial studies, respectively. The result was considered significant if p<0.05. A total of 670 studies were screened, resulting in 8 multicentre studies. There were significant differences in clinical response (RR: 1.39; 95%CI: 1.12–1.73; p = 0.003; I2= 35%), clinical remission (RR: 1.72; 95%CI: 1.17–2.53; p=0.006; I2= 26%), mean change of FC (RR: 624.29; 95%CI: 543.28-705.29; p<0.001; I2= 0%), mean change of CRP serum (RR: 9.71; 95%CI: 7.12–12.3; p<0.001), and mean MAdCAM-1 serum level (RR: 235.57; 95%CI: 203.80–267.33; p <0.001) between ontamalimab 75 mg and placebo after 12 wk of treatment. Meanwhile, adverse events from both groups were similar to those observed in patients treated with either placebo or ontamalimab. This study concluded that ontamalimab 75mg demonstrated significant efficacy in treating IBD, achieving superior outcomes in clinical response and clinical remission compared to placebo. Importantly, no cases of PML and significant adverse events were detected, indicating a favorable safety profile relative to other anti-MAdCAM-1 therapies.

Page 2 of 2 | Total Record : 15

 1   2 

Filter by Year

2025 2025


Reset
Filter By Issues
All Issue Vol 58 No 1 (2026) Vol 57 No 4 (2025) Vol 57 No 3 (2025) Vol 57 No 2 (2025) Vol 57 No 1 (2025) Vol 56 No 01 (2024) Vol 56 No 4 (2024) Vol 56 No 3 (2024) Vol 56 No 2 (2024)